Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arbutus Biopharma Corporation before investing.

In this article, we go over a few key elements for understanding Arbutus Biopharma Corporation’s stock price such as:

• Arbutus Biopharma Corporation’s current stock price and volume
• Why Arbutus Biopharma Corporation’s stock price changed recently
• Upgrades and downgrades for ABUS from analysts
• ABUS’s stock price momentum as measured by its relative strength

About Arbutus Biopharma Corporation (ABUS)

Before we jump into Arbutus Biopharma Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Want to learn more about Arbutus Biopharma Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, Arbutus Biopharma Corporation’s stock price was $4.375.

Arbutus Biopharma Corporation is up 0.57% from its previous closing price of $4.350.

During the last market session, Arbutus Biopharma Corporation’s stock traded between $4.309 and $4.380. Currently, there are approximately 192.35 million shares outstanding for Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Arbutus Biopharma Corporation Stock Price History

Arbutus Biopharma Corporation’s (ABUS) price is currently up 4.17% so far this month.

During the month of May, Arbutus Biopharma Corporation’s stock price has reached a high of $4.540 and a low of $4.165.

Over the last year, Arbutus Biopharma Corporation has hit prices as high as $5.100 and as low as $2.940. Year to date, Arbutus Biopharma Corporation’s stock is down 9.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Arbutus Biopharma Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there was 1 analyst who downgraded Arbutus Biopharma Corporation’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Arbutus Biopharma Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arbutus Biopharma Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arbutus Biopharma Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arbutus Biopharma Corporation (ABUS) by visiting AAII Stock Evaluator.

Relative Price Strength of Arbutus Biopharma Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Arbutus Biopharma Corporation has a weighted four-quarter relative price strength of 2.67%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how Arbutus Biopharma Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arbutus Biopharma Corporation Stock Price: Bottom Line

As of May 8, 2026, Arbutus Biopharma Corporation’s stock price is $4.375, which is up 0.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arbutus Biopharma Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.